[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-sarcoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-sarcoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,47,80,110,135,156,185,212,235,271,306,325,349,375,399],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644347","bridging-adolescent-and-young-adult-sarcoma-survivors-with-personalized-oncology-exercise-service-aya-one-a-pilot-intervention-100644347",false,"NCT07662239","Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention","AYA-ONE","Inclusion Criteria:\n\n* Diagnosed with a bone or soft tissue sarcoma\n* Age 15-39 at time of diagnosis\n* Age 15 and older at time of enrollment\n* Age 15-17 at time of enrollment, with assent from participant and consent from parent\u002Flegal guardian\n* Established patient of the DFCI Sarcoma Center or Jimmy Fund\n* Able to read and understand English (to complete required questionnaires and participate in training\u002Fcoaching)\n* Individuals who are not yet adults (teenagers) if they assent and their parents\u002Flegal guardians' consent to participation.\n\nExclusion Criteria:\n\n* Unstable cardiovascular disease in the last 6 months\n* Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, untreated substance use disorder, severe personality disorder)\n* Pregnant\n* Currently participating in physical or occupational therapy\n* Presence of medical conditions or medications that would prohibit participation in an exercise program\n* Meeting exercise guidelines of 150 minutes of moderate intensity\u002F75 minutes of vigorous intensity physical activity per week plus consistent strength training (at least once per week) over the past 3 months. Assessed via Godin Leisure Time Questionnaire by study staff.\n* Adults unable to consent","ALL","15 Years","39 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma. The study will assess the feasibility of a standardized triage system for referring AYAs with sarcoma to appropriate exercise and rehabilitation services, and will also examine changes in physical function and health-related quality of life before and after a 12-week personalized exercise program.",[27,28,29],"Sarcoma","Bone Sarcoma","Soft Tissue Sarcoma (STS)",[31,32,33],"sarcoma","bone sarcoma","soft tissue sarcoma","NOT_YET_RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":21},"2026-08-01",{"date":42,"type":21},"2027-02-01",{"name":44,"class":45},"Dana-Farber Cancer Institute","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100560022","phase-2-xl092-zanzalintinib-for-the-treatment-of-patients-with-metastatic-or-unresectable-leiomyosarcoma-bone-sarcoma-or-translocation-associated-soft-tissue-sarcoma-100560022","NCT06571734","XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma","A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma","Inclusion Criteria For Cohort 1 - Leiomyosarcoma:\n\n* Patients must have histologically confirmed leiomyosarcoma that has been clinically determined to be metastatic or unresectable. Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone at least 2 or more lines of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria For Cohort 2 - Bone Sarcoma:\n\n* Patients must have histologically confirmed diagnosis of metastatic or unresectable bone sarcoma. Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone at least 1 line of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria For Cohort 3 - Translocation-associated Soft Tissue Sarcoma:\n\n* Patients must have histologically confirmed diagnosis of metastatic or unresectable translocation-associated soft tissue sarcoma (TAS). Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone greater than 2 lines of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria for All Cohorts\u002FSarcoma Types\n\n* Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.\n* Patients must be aged ≥ 18 years on day of signing any informed consent documents.\n* Patients must exhibit a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale or \\> 70% on the Karnofsky Scale.\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL (without granulocyte colony-stimulating factor support within 21 days of screening sample collection)\n* Hemoglobin (Hgb) ≥ 9 g\u002FdL without transfusion within 21 days of screening laboratory sample collection\n* Platelets (PLT) ≥ 100,000\u002Fmm\\^3 (\\> 100 GI\u002FL) without transfusion within 21 days of screening laboratory sample collection\n* International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal ULN; for patients with Gilbert's disease, total bilirubin ≤ 3 x ULN\n* Alanine aminotransferase (AST) ≤ 3 x institutional ULN\n* Aspartate aminotransferase (ALT) ≤ 3 x institutional ULN\n* Alkaline phosphatase (ALP) ≤ 3 x institutional ULN; for patients with documented bone metastasis, ALP ≤ 5 x ULN\n* Serum creatinine ≤ 1.5 x institutional ULN OR calculated creatinine clearance ≥ 40 mL\u002Fmin ( ≥ 0.67 mL\u002Fsec) using the Cockcroft-Gault equation\n* Creatinine clearance ≥ 40mL\u002Fmin\n* Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg\u002Fmg ( ≤ 113.12 mg\u002Fmmol)\n* Patient of child-bearing potential (POCBP) and any of their partners with sperm-producing reproductive capability must agree to use a highly effective method of contraception throughout the course of the study and for 186 days after the last dose of treatment. Additional contraceptive method, such as a barrier method (e.g., condom) is also required\n* Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence), with partners of childbearing potential from time of informed consent, for the duration of study participation, and for 96 days following completion of therapy\n* Patients must have ejection fraction \\> 50% by either MUGA scan or echocardiogram.\n* Patients must be capable of understanding and complying with the protocol requirements.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have received previous treatment with XL092.\n* Patients who have received any type of small-molecule kinase inhibitor (including an investigational kinase inhibitor) within 14 days prior to study day 1 treatment.\n* Patients who have received \\> 2 prior tyrosine kinase inhibitor therapies as anticancer treatments.\n* Patients who have had prior chemotherapy, or radiation therapy within 4 weeks prior to start of study treatment unless they have recovered from their prior therapy (toxicity and\u002For complications) such that they now meet all other eligibility criteria\n* Patients who have received radiation therapy for bone metastasis within 14 days prior to registration\n* Patients who have undergone systemic treatment with radionuclides within 6 weeks (42 days) before first dose of study treatment\n* Patients with clinically relevant complications from prior radiation therapy requiring ongoing therapy, per the opinion of the treating investigator enrolling the patient.\n* Patients with a known prior or concurrent malignancy that is progressing or requires active treatment within 2 years of first dose of study treatment. Note: The following exceptions may be made:\n\n  * For patients with malignancies like basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer; or superficial skin cancers, localized low-grade tumors deemed cured and not treated with systemic therapy, and incidentally diagnosed prostate cancer if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.\n  * For patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed. Note: Eligible patients must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n* Patients who are on concomitant anticoagulation therapy with oral anticoagulants (e.g., warfarin or direct thrombin and factor Xa inhibitors) and platelet inhibitors (e.g., clopidogrel). Note: Allowed anticoagulants are low-dose aspirin for cardioprotection (per local applicable guidelines) and low molecular weight heparins (LMWH). Therapeutic doses of LMWH are not permitted in patients with brain metastases. Note: Patients must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first study treatment, whichever is longer.\n* Patients who are taking any complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks (14 days) prior to start of treatment. Note: taking complementary medications to treat symptoms of the cancer is allowed.\n* The patient has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes)\n    * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic of \\> 90 mm Hg diastolic despite optimal antihypertensive treatment\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant ischemic events within 12 months prior to first dose of study treatment. Note: Patients who did not require prior anticoagulant therapy may be eligible must be discussed and approved by the principal investigator (PI)\n    * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous or non-cerebrovascular accident (CVA)\u002FTIA arterial thromboembolic events within 6 months before to first dose of study treatment.\n    * Prior history of myocarditis\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n    * Tumors invading the GI tract from external viscera\n    * Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n    * Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess must be confirmed prior to first dose of study treatment\n    * Known gastric or esophageal varices\n    * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months unless cause of obstruction is definitively managed and subject is asymptomatic\n* Patients with clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 84 days prior to registration.\n* Symptomatic cavitating pulmonary lesions or endobronchial disease (asymptomatic or radiated lesions allowed).\n* Lesions invading major blood vessel including but not limited to inferior vena cava, pulmonary artery, or aorta.\n\nNote: Patients with intravascular tumor extension (e.g., tumor thrombus in renal vein or inferior vena cava) may be eligible following PI approval\n\n* Patients who are capable of donating eggs for the purpose of reproduction must not do so throughout the course of the study and for 186 days after the last dose of treatment\n* Patients who are capable of donating sperm for the purpose of reproduction must not do so throughout the course of the study and for 96 days after the last dose of treatment\n* Other clinically significant disorders that would preclude safe study participation, including, but not limited to:\n\n  * Active infection requiring systemic treatment. Note: This criterion applies only at enrollment; if a patient develops an infection while on study treatment, they may continue to receive study treatment. Note: prophylactic antibiotic treatment is allowed\n  * Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness\n  * Known positive test for or suspected infection with SARS-CoV-2 within one month prior to enrollment. Note: Demonstration that the patient has fully recovered from the infection is required to be eligible for enrollment\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if they are due to tumor-associated skin lesions\n  * Malabsorption syndrome\n  * Pharmacologically uncompensated, symptomatic hypothyroidism\n  * Moderate to severe hepatic impairment (Child-Pugh B or C)\n  * Requirement for hemodialysis or peritoneal dialysis\n  * History of solid organ or allogenic stem cell transplant\n* Recent surgery within the following parameters:\n\n  * Major surgery (e.g., GI surgery or removal\u002Fbiopsy of brain metastasis) within 8 weeks prior to study treatment\n  * Minor surgery (e.g., simple excision, tooth extraction) within 5 days prior to first dose of study treatment. Note: if a patient has had a recent surgery outside of the proscribed interval, complete wound healing from said surgery must have occurred prior to first dose of study treatment. Note: Fresh tumor biopsies should be performed at least 5 days prior to registration. Patients with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) prior to first dose of study treatment Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility\n* Patients with any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) grade \\> 1 at baseline from a previous anticancer therapy, with the following exceptions:\n\n  * Alopecia, vitiligo, and the laboratory values\n  * Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the treating physician\n  * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with XL092 may be included only after consultation with the principal investigator\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to XL092\n* Patients who are pregnant (positive serum or urine test within 72 hours prior to enrollment) or nursing. Pregnant people are excluded from this study because XL092 is a next-generation tyrosine kinase inhibitor with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the nursing parent with XL092, breastfeeding should be discontinued if the nursing parent is treated with XL092. Note: If a urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, per the opinion of the treating investigator\n* XL092 is administrated orally; patients who are unable to swallow, retain, and\u002For absorb pills are not eligible for this study\n* Patients who are currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of treatment\n* Other conditions which, in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study","18 Years",{"count":56,"type":21},73,[58],"PHASE2","This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, interferes with cell communication and growth and may prevent tumor growth. Giving XL092 may kill more tumor cells in patients with metastatic or unresectable leiomyosarcoma. The trial has now been expanded to treat additional sarcoma types that are sensitive to tyrosine kinase inhibitors (TKIs) such as translocation-associated soft tissue sarcoma (such as synovial sarcoma), and bone sarcoma (including osteosarcoma and Ewing sarcoma).",[61,62,28,63,64,65,66,67,68,69],"Metastatic Leiomyosarcoma","Unresectable Leiomyosarcoma","Translocation-associated Soft Tissue Sarcoma","Synovial Sarcomas","Osteosarcoma Metastatic","Ewing Sarcoma","Ewing Sarcoma Metastatic","Sarcoma Metastatic","Sarcoma of Bone","RECRUITING",{"date":72,"type":38},"2026-06-18",{"date":74,"type":38},"2024-09-19",{"date":76,"type":21},"2033-07-01",{"name":78,"class":45},"Northwestern University",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":79},"100638252","preoperative-immunonutrition-in-patients-with-bone-and-soft-tissue-sarcomas-100638252","NCT07609329","Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas","Effect of Preoperative Immunomodulatory Nutritional Intervention on Postoperative Complications and Sarcopenia in Patients With Bone and Soft Tissue Sarcomas","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n* Adult patients aged 18 years or older.\n* Histologically confirmed bone sarcoma or soft tissue sarcoma.\n* Localized or oligometastatic disease.\n* Indicated for planned orthopedic tumor resection.\n* Preoperative interval allowing administration of the nutritional intervention for at least 7 days, with 14 days preferred when clinically feasible.\n* Ability to receive oral nutritional supplementation.\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Participants will be excluded if any of the following criteria are present:\n* Indication for urgent surgery.\n* Disseminated disease with more than five metastases.\n* Ongoing parenteral nutrition before study enrollment.\n* Inability to receive oral intake.\n* Severe hepatic failure.\n* Severe renal failure.",{"count":88,"type":21},100,[24],"This study will evaluate whether a short nutritional intervention before surgery can improve recovery in patients with bone and soft tissue sarcomas.\n\nPatients with these tumors often have a higher risk of poor nutrition and loss of muscle mass. These problems may increase the risk of complications after major orthopedic surgery.\n\nParticipants will be randomly assigned to one of two groups. One group will receive a special oral nutritional supplement twice daily before surgery, in addition to standard care. The other group will receive standard care without the preoperative nutritional supplement.\n\nThe main aim of the study is to compare the rate of clinically relevant postoperative complications within 30 days after surgery. The study will also evaluate changes in muscle mass on CT scans, blood markers of nutrition and inflammation, nutritional risk, functional status, length of hospital stay, and tolerance of the nutritional supplement.",[28,92,93,94,95],"Soft Tissue Sarcoma","Sarcopenia","Malnutrition","Postoperative Complications",[27,97,98,94,99,100,93],"Bone sarcoma","Soft tissue sarcoma","Preoperative Nutrition","Immunonutrition","2026-05-19",{"date":103,"type":38},"2026-05-27",{"date":105,"type":38},"2026-04-01",{"date":107,"type":21},"2028-12-31",{"name":109,"class":45},"St. Anne's University Hospital Brno, Czech Republic",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100526066","study-assessing-the-effects-of-early-psychiatric-referral-on-mental-health-and-quality-of-life-in-people-with-sarcoma-100526066","NCT06129903","Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma","The Effect of Enhanced Behavioral Healthcare on Self-Reported Depression, Anxiety, and Health-Related Quality of Life Among Patients With Musculoskeletal Sarcoma Undergoing Surgery: A Randomized Pilot Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Tissue diagnosis of primary bone or soft tissue sarcoma\n\n  o Note: high suspicion of sarcoma on history and imaging acceptable, if reviewed and approved by the PI\n* Presenting to the Orthopaedic Surgery Service\n* Treatment plan includes surgery at MSK for treatment of the primary sarcoma\n* No previous treatment for sarcoma\n* Proficient in English\n\n  * As determined by use of the Census-LEP question\n  * The patient's response to the question: \"How well do you speak English?\" must be \"very-well\" for inclusion. Additionally, English must be identified as the patient's preferred language for discussing healthcare.\n\nExclusion Criteria:\n\n* Significant psychiatric disturbance determined from self-report and\u002For chart review, sufficient, in the investigator's judgment, to preclude participation in the study\" (e.g., underlying severe mental illness, h\u002Fo suicide attempts, or h\u002Fo psychiatric admissions) Clinical concern at the time of randomization of mental health urgency or emergency requiring evaluation; urgency and emergency will be defined as moderate or high scores, respectively, on the CSSR-S or according to the judgment of the orthopaedic physician evaluating the patient\n* Note: investigators considered exclusion of patients with no or mild symptoms of anxiety and depression, however due to risk of new symptoms arising during the course of treatment, risk of underreporting, risk of under detection, and given prior data on the high prevalence of symptoms, we elected to include all patients in this pilot study.",{"count":118,"type":21},60,[24],"The purpose of this study is to investigate the feasibility of early access to mental healthcare during sarcoma treatment as well as to assess the association between early access to psychiatric care and depression, anxiety, postoperative outcomes, and patient satisfaction in patients undergoing surgery for musculoskeletal sarcoma.",[27,28,92],[27,28,92,123,124,125],"Quality of Life","23-247","Memorial Sloan Kettering Cancer Center","2026-05-13",{"date":128,"type":38},"2026-05-15",{"date":130,"type":38},"2023-11-07",{"date":132,"type":21},"2026-11-07",{"name":125,"class":45},8,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":79},"100487022","phase-1-a-first-in-human-phase-1-trial-of-t-cell-membrane-anchored-tumor-targeted-il12-attil12--t-cell-therapy-in-subjects-with-advancedmetastatic-soft-tissue-and-bone-sarcoma-100487022","NCT05621668","A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced\u002FMetastatic Soft Tissue and Bone Sarcoma","Inclusion criteria:\n\n1. Age .12 years old\n2. Histologically-confirmed locally advanced or metastatic soft tissue or bone sarcoma\n3. Osteosarcoma expansion cohort: histologically confirmed unresectable recurrent\u002Fmetastatic osteosarcoma\n4. Evaluable disease.\n5. Patients must have received at least 1 prior line of systemic therapy for the treatment of sarcoma, unless no standard therapy exists for a specific sarcoma subtype\n6. Prior Cancer Therapy . At least 3 weeks must have elapsed since the last cytotoxic chemotherapy or immunotherapy prior to leukapheresis\u002FPBMC collection.\n\n   * For targeted therapies, at least 4 half-lives or 3 weeks must have elapsed prior to leukapheresis (whichever is shorter).\n7. Standard of care anti-cancer therapy will be permitted following leukapheresis but prior to initiation of cyclophosphamide such that:\n\n   . At least 3 weeks must have elapsed since last cytotoxic chemotherapy or immunotherapy prior to starting treatment with cyclophosphamide.\n\n   . For targeted therapies, at least 4 half-lives or 3 weeks must have elapsed prior to initiation of treatment with cyclophosphamide (whichever is shorter).\n\n   . At least 2 weeks must have elapsed since last radiation therapy prior to cyclophosphamide.\n\n   . Investigational anti-cancer therapy will not be permitted.\n8. ECOG performance status of 0 or 1 (Performance level as measured by Karnofsky for patients . 16 years of age or Lansky for patients \\\u003C 16 years of age, see Appendix B)\n9. Participants must be willing to undergo tumor biopsy\n\n   . Patients in whom biopsy is medically contraindicated or otherwise high risk will not be excluded and may forego research tumor biopsies\n10. Patients must have organ and marrow function as defined below\n11. Absolute neutrophil count (ANC) . 1 K\u002FuL, Hemoglobin . 9 g\u002FdL, Platelets.100 K\u002Fmm3\n12. Serum creatinine . 2 mg\u002FdL OR creatinine clearance \\> 50 mL\u002Fmin\n13. Aspartic transaminase (AST) . 1.5 x upper limit of normal (ULN), Alanine transaminase (ALT) . 1.5 x ULN, Bilirubin . 1.5 x ULN\n14. Cardiac function . LVEF \\>50%\n15. Pulmonary function\n\n    . Oxygen saturation \\>92% on room air\n    * Total lung capacity \\>70% of predicted\n    * DLCO \\>60% of predicted\n16. Women of childbearing potential (WOCBP) must agree to use method(s) of contraception: at least one highly effective or two effective accepted methods of contraception to avoid conception throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before start of therapy, and while women are on study for up to 3 months after T cell infusion. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal\n17. Men must be willing and able to use an acceptable method of birth control such as latex condom during the dosing period and for at least 3 months after completion of the study agent administration (T cell infusion) if their sexual partners are WOCBP.\n18. Signed Informed Consent and if applicable, pediatric assent\n\nExclusion criteria:\n\n1. Known sensitivity to cyclophosphamide and\u002For study agents Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded\n2. Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression. Subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of attIL12-T cells are permitted to enroll. 3. Presence of metastatic disease in or near vital or critical structures that in the judgement of the treating physician in communication with PI or their delegate may lead to concern of immediate risk for harm from the inflammatory response.\n\n4\\. Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment at the time of leukapheresis or attIL12 T cell infusion.\n\n1. Standard of care anti-cancer therapy will be permitted following leukapheresis and prior to initiation of cyclophosphamide as bridging therapy (per section 12.4.1).\n2. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.\n3. In addition, local treatment (eg, by local surgery, radiotherapy, or ablation) of isolated lesions for palliative intent is acceptable beyond 30 days following attIL12 T cell administration with prior consultation and in agreement with the PI.\n4. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5 Grade 0 or 1 with the exception of alopecia and laboratory values listed per the inclusion criteria. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by any of the investigational products may be included (eg, hearing loss) after consultation with the PI.\n5. Investigational therapy for supportive care (e.g. COVID vaccine) will be permitted, as long as it is reviewed and discussed with the PI.\n\n   5\\. History of primary immunodeficiency, solid organ transplantation, or previous clinical diagnosis of tuberculosis.\n\n   6\\. Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products 7. Major surgery (as defined by the investigator) within 4 weeks prior to first dose of treatment or if still recovering from prior surgery. Biopsy as per study protocol is allowed 8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from the study agents, or compromise the ability of the subject to give written informed consent.\n\n   9\\. Subjects with cognitive impairment, including adults with cognitive impairment such as trisomy 21 or similar conditions are not specifically excluded from participation, such that appropriate written informed consent is obtained from the parent or legal guardian and they are able to complete with the study protocol requirements and treatment.\n\n   10\\. Active concurrent second malignancy 11. Pregnant or lactating women 12. Any positive test result for hepatitis B or C virus indicating acute or chronic infection 13. Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome","12 Years",{"count":20,"type":21},[144],"PHASE1","To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.",[92,28],"2026-04-28",{"date":149,"type":38},"2026-05-04",{"date":151,"type":38},"2023-09-08",{"date":153,"type":21},"2027-09-30",{"name":155,"class":45},"M.D. Anderson Cancer Center",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":174,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},"100319721","assessment-of-healing-and-function-after-reconstruction-surgery-for-bone-sarcomas-100319721","NCT03442465","Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas","Assessment of Healing and Function After Surgical Reconstruction for Neoplasms Involving Bone","Inclusion Criteria:\n\n* All patients undergoing reconstructive surgery for neoplasms involving bone on the orthopaedic surgery service at MSK\n* Current or prior history of primary neoplasms involving osseous structures, including all subtypes\n* Confirmation of diagnosis that has been performed by the MSK's Department of Pathology via direct review of tissue\u002Fslides\n* Patients must read and understand English\n* Age \\>\u002F=4\n* Patients must read and understand English\n\nExclusion Criteria:\n\n* Patients that weight \\\u003C17 kilograms","4 Years",{"count":165,"type":21},300,"OBSERVATIONAL","The purpose of this study is to look at the amount of function that returns in participants that have reconstruction with bone graft or artificial device and in participants who have tumor surgery plus regenerative osseous surgery.\n\nThe study will look at the level of function for a period of 3 years after the surgery. Another purpose of this study is to look at how well the bone heals in participants undergoing regenerative surgery",[28,169,170,171,172,173],"Osteosarcoma","Chondrosarcoma","Ewing's Sarcoma","Osseous Sarcoma","Bone Neoplasm",[175,125],"18-014","2026-04-16",{"date":178,"type":38},"2026-04-17",{"date":180,"type":38},"2018-02-14",{"date":182,"type":21},"2027-02-14",{"name":125,"class":45},5,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":16,"minAge":54,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":196,"conditions":197,"keywords":198,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":79},"100443181","assessment-of-the-functional-outcome-and-quality-of-life-in-sarcoma-patients-100443181","NCT05051059","Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients","QOLSarcoma","Inclusion Criteria:\n\n* Patients who underwent limb salvage surgery for bone or soft tissue sarcoma of the lower extremity at UZ Leuven\n* 18 to 95 years old\n* Patients should be at least one year post surgery\n* Informed consent has obtained\n\nExclusion Criteria:\n\n* Patients who received major prior surgery of the lower limbs or with any pathology, injury or disorder known to affect the locomotor system\n* Skeletally immature individuals\n* No informed consent has obtained",true,"95 Years",{"count":118,"type":21},[24],"Primary bone and soft tissue sarcomas are an exceptionally rare form of cancer, collectively accounting for only 1% of all malignancies diagnosed. Sarcomas often occur in the patients' extremities and treatment typically involves limb salvage surgery with bone and\u002For muscle resection. These surgeries often leave the patients with disfigurements, psychological trauma, and functional disabilities. Perhaps, the most difficult and life-altering decision that patients (and their parents) with primary bone sarcomas about the knee joint have to make, involves choosing the type of surgical procedure that will provide them with the outcome that meets their functional as well as aesthetic expectations.\n\nIn literature, the quality of life for patients with osteosarcoma around the knee joint after three different surgical procedures, that is, amputation, endoprosthetic reconstruction and rotationplasty was evaluated. There was found that patients treated with rotationplasty showed significantly higher functional scores compared to the two other groups of patients. Also, researchers investigated the long-term quality of life after bone sarcoma surgery around the knee joint and found that, despite the functional disability, survivors were busy with work, study, relationships, and sometimes they have founded a family.\n\nMost published reports in the literature on assessment of gait in the lower-extremity sarcoma survivors were focused on bone sarcoma patients after wide resection and endoprosthetic reconstruction. To the knowledge of the investigator, there has been no published studies on gait analysis after resection of soft tissue sarcomas (STS) of the lower extremity. The rare and heterogeneous aspects of STS and the paucity of knowledge of movement strategies in these patients hinder the development of effective rehabilitation protocols for recovering movement after resection of STS in the lower limb.",[92,28],[199,200,201,202],"Lower extremities","Health related quality of life","Functional outcome","Limb salvage surgery","2026-03-12",{"date":205,"type":38},"2026-03-16",{"date":207,"type":38},"2021-10-01",{"date":209,"type":21},"2026-12",{"name":211,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":46},"100441816","comparing-carbon-ion-therapy-surgery-and-proton-therapy-for-management-of-pelvic-sarcomas-involving-the-bone-100441816","NCT05033288","Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone","Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue\u002FBone) Involving the Bone","Inclusion Criteria:\n\n* Males and females \\>= 15 years of age\n* Newly diagnosed, histologic confirmation of pelvic chordoma, chondrosarcoma, osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone involvement or non-RMS soft tissue sarcoma with bone involvement\n* No evidence of distant sarcoma metastases as determined by clinical examination and any form of imaging\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\\\u003C 2\n* Patients capable of childbearing must agree to use adequate contraception\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Ability to provide written informed consent\n* Chemotherapy per institutional guidelines is allowed\n\nExclusion Criteria:\n\n* Patients receiving palliative treatment\n* Recurrent disease\n* Males and females \\\u003C 15 years of age\n* Previous radiation therapy to the site of the sarcoma or area surrounding it such that it would be partially or completely encompassed by the radiation volume needed to treat the current sarcoma. In other words, treatment on this study would require re-irradiation of tissues\n* Patients with distant sarcoma metastases\n* Benign pelvic bone histologies\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception",{"count":220,"type":21},72,"This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon\u002Fproton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life compared to surgery and disease control compared with proton therapy.",[28,170,223,224,225],"Chordoma","Ewing Sarcoma of Bone","Pelvic Rhabdomyosarcoma","2026-03-11",{"date":228,"type":38},"2026-03-13",{"date":230,"type":38},"2022-01-20",{"date":232,"type":21},"2031-08-30",{"name":234,"class":45},"Mayo Clinic",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100416140","phase-2-efficacy-of-regorafenib-combined-with-best-supportive-care-as-maintenance-treatment-in-high-grade-bone-sarcomas-patients-100416140","NCT04698785","Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients","A Multicentre Phase II Study of Efficacy of Regorafenib as Maintenance Treatment in Patients With High Grade Bone Sarcomas at Diagnosis or Relapse and Without Complete Remission After Standard Treatment","REGOMAIN","INCLUSION CRITERIA:\n\nI1. Age ≥ 12 years at the day of consenting to the study;\n\nI2. Patients must have histologically confirmed high-grade sarcomas of bone primary localisation, including but not limited to: Osteosarcomas, Ewing sarcomas, Chondrosarcomas, Undifferenciated Pleomorphic Sarcomas (UPS), Leiomyosarcomas (LMS) and Angiosarcomas\n\nI3. Evaluable residual disease not amenable to resection after multimodal treatment principles either at diagnosis (after standard multimodal treatment based on the histological subtype) or at relapse (chemotherapy)\n\nI4. Non progressive disease (defined by the investigator according to the RECIST version 1.1 Appendix 1) at study entry;\n\nI5. Interval between the date of last anticancer treatment (chemotherapy or surgery) and the start date of regorafenib: at least 4 weeks but no longer than 2 months;\n\nI6. Life expectancy of greater than 6 months;\n\nI7. Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C 2 (Karnofsky ≥ 70%) (Appendix 2);\n\nI8. Adequate bone marrow and organ function defined by the following laboratory results:\n\na. Bone marrow: i. Absolute neutrophil count ≥ 1.5 Giga\u002Fl ii. Platelets ≥ 100 Giga\u002Fl iii. Haemoglobin≥ 9 g\u002Fdl\n\nb. Hepatic function: i. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN) (≤ 5.0 × ULN for patients with liver involvement of their cancer) ii. Bilirubin ≤1.5 X ULN iii. Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase \\> 2.5 ULN, hepatic isoenzymes 5-nucleotidase or gamma-glutamyltransferase (GGT) tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and\u002For GGT \\\u003C 1.5 x ULN.\n\nc. Renal function: i. Serum creatinine ≤ 1.5 x ULN ii. Glomerular Filtration Rate (GFR) ≥ 30 ml\u002Fmin\u002F1.73m2 according to the Modified Diet in Renal Disease (MDRD) abbreviated formula iii. Spot urine must not show ≥ 1 \"+\" protein in urine or the patient will require a repeat urine analysis. If repeat urinalysis shows 1 \"+\" protein or more, a 24-hour urine collection will be required and must show total protein excretion \\\u003C 1000 mg\u002F24 hours\n\nd. Coagulation: International Normalized Ratio (INR)\u002FPartial Thromboplastin Time (PTT) ≤1.5 x ULN; Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR\u002FPTT is stable based on a measurement that is pre-dose as defined by the local standard of care;\n\ne. Pancreatic function: Lipase ≤ 1.5 x ULN\n\nI9. Recovery to anticancer-treatment related NCI-CTCAE v5 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug\u002Fprocedure related toxicity (except alopecia, anaemia, and hypothyroidism);\n\nI10. Women of childbearing potential and male patients must agree to use adequate contraception (including at least the use of condoms) for the duration of treatment and for 7 months (210 days) in women of childbearing potential or 4 months (120 days) in men sexually active with women of childbearing potential after the last dose of regorafenib\n\nI11. Patients, and their parents when applicable, must sign and date an informed consent document indicating that they have been informed of all the pertinent aspects of the trial prior to enrolment;\n\nI12. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures;\n\nI13. Patients affiliated to the Social Security System\n\nI14. Body Surface Area (BSA) ≥ 1.30m² at the time of consenting to the study\n\nEXCLUSION CRITERIA:\n\nE1. Prior treatment with any VEGFR inhibitor (thus, any prior exposure to regorafenib, sunitinib, sorafenib, pazopanib, bevacizumab, or other VEGFR inhibitor);\n\nE2. All soft tissue sarcomas (including but not limited to soft tissue osteosarcoma), and chordomas;\n\nE3. Prior history of malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within 3 years prior to randomization;\n\nE4. Cardiovascular dysfunction defined by:\n\n* Left ventricular ejection fraction (LVEF) \\\u003C 50%,\n* Congestive heart failure ≥ New York Heart Association (NYHA) class 2,\n* Myocardial infarction \\\u003C 6 months prior to first study drug administration,\n* Cardiac arrhythmias requiring therapy (beta blockers or digoxin are permitted),\n* Unstable (angina symptoms at rest) or new-onset angina within the last 3 months prior to first study drug administration;\n* Uncontrolled hypertension (systolic blood pressure \\> 150 mm Hg or diastolic pressure \\> 90 mm Hg despite optimal treatment);\n* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the last 6 months before the first study drug administration;\n\nE5. Major surgical procedure, open biopsy or significant traumatic injury within 28 days before the first study drug administration;\n\nE6. Ongoing infection \\> Grade 2 according to NCI-CTCAE v5;\n\nE7. Known history of human immunodeficiency virus infection;\n\nNota Bene: Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate in the study if they meet the following criteria :\n\n1. No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months prior to enrolment;\n2. No history of AIDS-defining cancers (e.g. Kaposi's sarcoma, aggressive B-cell lymphoma and invasive cervical cancer);\n3. Subjects should be on established anti-retroviral therapy for at least 4 weeks and have an HIV viral load of \\\u003C 400 copies\u002FmL prior to enrolment;\n\nE8. Active or chronic hepatitis B or C requiring treatment with antiviral therapy; Nota Bene: Subjects with a history of hepatitis B or C who have normal alanine aminotransferase (ALT) and are hepatitis B surface antigen negative and\u002For have undetectable HCV RNA are eligible\n\nE9. Dehydration according to NCI-CTCAE v5 Grade \\>1;\n\nE10. Difficulties to swallow oral medication and\u002For any mal-absorption condition and\u002For any Gastrointestinal (GI) disease that may significantly alter the absorption of regorafenib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection);\n\nE11. Patients with seizure disorder requiring medication;\n\nE12. Concurrent enrolment in another clinical trial in which investigational therapies are administered;\n\nE13. Known hypersensitivity to the active substance or to any of the excipients;\n\nE14. Pregnant women, women who are likely to become pregnant or are breast-feeding. Women of childbearing potential must have a negative serum β-Human Chorionic Gonadotropin (HCG) pregnancy test within 7 days prior randomization;\n\nE15. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;\n\nE16. Patients with history of non-compliance to medical regimens or unwilling or unable to comply with the protocol;\n\nE17. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent;\n\nE18. Non-healing wound, non-healing ulcer, or non-healing bone fracture;\n\nE19. Patients with evidence or history of any bleeding diathesis, irrespective of severity;\n\nE20. Any haemorrhage or bleeding event ≥ CTCAE v5 Grade 3 within 4 weeks prior to the first study drug administration;\n\nE21. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results;\n\nE22. Patients using prohibited concomitant and\u002For concurrent medications (see section \"Prohibited concomitant\u002Fconcurrent treatments);\n\nE23. Patients under tutorship or curatorship.",{"count":244,"type":21},36,[58],"This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.\n\nPatients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy after standard line therapy completion.\n\nProgression free rate (PFR) data will be collected and analysed for all included patients to evaluate if regorafenib + BSC can be considered as an interesting treatment for further investigations in this indication.",[28,169],[97,169,249,250,251,252,253,254,255,256,257,258,259,260],"Maintenance therapy","Regorafenib","Progression-free rate","Objective response rate","Disease control rate","Overall survival","Quality of life","Tolerance","Tyrosine inhibitor kinase","Multitarget inhibitor","High-grade","Progression-Free survival","2026-02-13",{"date":263,"type":38},"2026-02-17",{"date":265,"type":38},"2021-07-21",{"date":267,"type":21},"2026-07-21",{"name":269,"class":45},"Centre Leon Berard",16,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":270},"100366742","efficacy-and-safety-of-regorafenib-as-maintenance-therapy-after-first-line-treatment-in-patients-with-bone-sarcomas-100366742","NCT04055220","Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas","A Multicentre Exploratory Phase II Study Describing the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas","REGOSTA","INCLUSION CRITERIA :\n\nI1. Age ≥ 12 years at the day of consenting to the study;\n\nI2. Patients must have histologically confirmed diagnosis of primary bone sarcoma including but not limited to: Osteosarcomas, Ewing sarcomas, Chondrosarcomas, Undifferentiated Pleomorphic Sarcomas (UPS), Leiomyosarcomas (LMS) and Angiosarcomas;\n\nI3. Prior treatment for localized or metastatic disease for bone sarcoma must have been completed, consisting of a standard multimodal treatment based on the histological subtype:\n\nFor OS, (excepted head and neck localisations), neoadjuvant and\u002For adjuvant chemotherapy should include methotrexate-based regimen for patients \\\u003C 18 years old; patients ≥ 18 years old may have received either methotrexate-based regimen or anthracycline and cisplatin-based regimen For head and neck OS, neoadjuvant and\u002For adjuvant chemotherapy should include adriamycin, cisplatin or ifosfamide-based regimen.\n\nFor non-OS, neoadjuvant and\u002For adjuvant chemotherapy should include adriamycin and\u002For cisplatin-based regimen.\n\nI4. Recovery to NCI-CTCAE v5 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug\u002Fprocedure related toxicity (except alopecia, anaemia, and hypothyroidism);\n\nI5. Interval between the last chemotherapy administration and the date of randomisation: at least 4 weeks but no longer than 2 months;\n\nI6. Confirmed complete remission or no evidence of disease (for metastatic disease);\n\nPatients with pulmonary micro nodules can be included provided they do not meet the following criteria:\n\n* At least one lung nodule of 10mm or more\n* And\u002For at least two nodules well limited between 6-9mm\n* And\u002For at least 5 nodules well limited of 5mm or less All the other situations will be considered as doubtful lesions except in case of metastatic disease confirmed during the lung surgery of the residual lung lesions after pre-operative chemotherapy. If no other metastatic localisation is detected at the initial staging, the patient will be considered as localised disease and eligible for randomisation.\n\nI7. Life expectancy of greater than 12 months;\n\nI8. Karnofsky Performance status ≥70 (patients younger than 18-year old) or ECOG performance status \\\u003C 2 (adult patients) ;\n\nI9. Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days of study treatment initiation:\n\n* Absolute neutrophil count ≥ 1.5 Giga\u002Fl\n* Platelets ≥ 100 Giga\u002Fl\n* Haemoglobin≥ 9 g\u002Fdl\n* Serum creatinine ≤ 1.5 x ULN\n* Glomerular filtration rate (GFR) ≥30 ml\u002Fmin\u002F1.73m2 according to the Modified Diet in Renal Disease (MDRD) abbreviated formula\n* AST and ALT ≤2.5 x ULN ( ≤5.0 × ULN for patients with liver involvement of their cancer)\n* Bilirubin ≤1.5 X ULN\n* Alkaline phosphatase ≤2.5 x ULN (≤5 x ULN in patient with liver involvement of their cancer). If Alkaline phosphatase \\> 2.5 ULN, hepatic isoenzymes 5-nucleotidase or GGT tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and\u002For GGT \\\u003C 1.5 x ULN.\n* Lipase ≤1.5 x ULN\n* Spot urine must not show ≥ 1 \"+\"protein in urine or the patient will require a repeat urine analysis. If repeat urinalysis shows 1 \"+\" protein or more, a 24-hour urine collection will be required and must show total protein excretion \\\u003C1000 mg\u002F24 hours\n\nI10. INR\u002FPTT ≤1.5 x ULN; Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR\u002FPTT is stable based on a measurement that is pre-dose as defined by the local standard of care;\n\nI11. Women of childbearing potential and male patients must agree to use adequate contraception (Appendix 4) for the duration of treatment and for 7 months (210 days) in WOCBP or 4 months (120 days) in men sexually active with WOCBP after the last dose of regorafenib;\n\nI12. Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days prior randomization and\u002For urine pregnancy test within 48 hours before the first administration of the study treatment;\n\nI13. Patients, and their parents when applicable, must sign and date an informed consent document indicating that they have been informed of all the pertinent aspects of the trial prior to enrolment;\n\nI14. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures;\n\nI15. Patients covered by a medical insurance.\n\nI16. Body Surface Area (BSA) ≥ 1.30m² at the time of consenting to the study.\n\nNON-INCLUSION CRITERIA :\n\nE1. Prior treatment with any VEGFR inhibitor (thus, any prior exposure to sunitinib, sorafenib, pazopanib, bevacizumab, or other VEGFR inhibitor);\n\nE2. All soft tissue sarcomas (including but not limited to soft tissue osteosarcomas and Ewing soft tissue sarcomas) and chordomas;\n\nE3. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within 3 years prior to randomization;\n\nE4. Cardiovascular dysfunction:\n\n* Left ventricular ejection fraction (LVEF) \\\u003C 50%,\n* Congestive heart failure ≥ New York Heart Association (NYHA) class 2,\n* Myocardial infarction \\\u003C 6 months prior to first study drug administration,\n* Cardiac arrhythmias requiring therapy (beta blockers or digoxin are permitted),\n* Unstable (angina symptoms at rest) or new-onset angina within the last 3 months prior to first study drug administration;\n\nE5. Uncontrolled hypertension (systolic blood pressure \\> 150mmHg or diastolic pressure \\> 90 mmHg despite optimal treatment);\n\nE6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the last 6 months before the first study drug administration;\n\nE7. Major surgical procedure, open biopsy or significant traumatic injury within 28 days before the first study drug administration;\n\nE8. Ongoing infection \\> Grade 2 according to NCI-CTCAE v5;\n\nE9. Known history of human immunodeficiency virus (HIV) infection;\n\nNota Bene: Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate in the study if they meet the following criteria:\n\n1. No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months prior to enrolment;\n2. No history of AIDS-defining cancers (e.g. Kaposi's sarcoma, aggressive B-cell lymphoma and invasive cervical cancer);\n3. Subjects should be on established anti-retroviral therapy for at least 4 weeks and have an HIV viral load of \\\u003C 400 copies\u002FmL prior to enrolment;\n\nE10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy; Nota Bene: Subjects with a history of hepatitis B or C who have normal alanine aminotransferase (ALT) and are hepatitis B surface antigen negative and\u002For have undetectable HCV RNA are eligible;\n\nE11. Dehydration according to NCI-CTC v5 Grade \\>1;\n\nE12. Difficulties to swallow oral medication and\u002For any mal-absorption condition and\u002For any Gastrointestinal (GI) disease that may significantly alter the absorption of regorafenib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection);\n\nE13. Patients with seizure disorder requiring medication;\n\nE14. Concurrent enrolment in another clinical trial in which investigational therapies are administered;\n\nE15. Known hypersensitivity to the active substance or to any of the excipients;\n\nE16. Pregnant women, women who are likely to become pregnant or are breast-feeding\n\nE17. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;\n\nE18. Patients with history of non-compliance to medical regimens or unwilling or unable to comply with the protocol;\n\nE19. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent;\n\nE20. Non-healing wound, non-healing ulcer, or non-healing bone fracture;\n\nE21. Patients with evidence or history of any bleeding diathesis, irrespective of severity;\n\nE22. Any haemorrhage or bleeding event ≥ CTCAE v5 Grade 3 within 4 weeks prior to the first study drug administration;\n\nE23. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results;\n\nE24. Patients using prohibited concomitant and\u002For concurrent medications (see section \"Prohibited concomitant\u002Fconcurrent treatments);\n\nE25.Patients under tutorship or curatorship.",{"count":280,"type":21},168,[24],"Randomized, non-comparative, multicentre exploratory phase II study.\n\nTwo arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12 months as maintenance therapy after first line therapy, whereas in the second arm, patients will be kept under surveillance (standard of care). Regardless of their study arm, all the patients will be followed up until end of the study.\n\nThe comparison between these two arms will allow to determine whether or not regorafenib is efficient for disease control, in terms of Relapse-Free Survival improvement.",[28,169,66,170,284,285,286],"Undifferentiated Pleomorphic Sarcoma","Leiomyosarcoma","Angiosarcoma",[249,288,250,289,290,291,292,293,254,255,294,97,169,295,296,297,298,299],"First line therapy","Randomization","Double-blinded","Placebo controlled","Relapse-free survival","Time to treatment failure","Compliance","Efficacy","Complete response","Tyrosine kinase inhibitor","Multi-target inhibitor","Safety",{"date":263,"type":38},{"date":302,"type":38},"2020-03-03",{"date":304,"type":21},"2026-10-01",{"name":269,"class":45},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":79},"100547518","evaluation-of-tumor-resection-guided-by-intraoperative-indocyanine-green-dye-fluorescence-angiography-in-patients-with-sarcoma-100547518","NCT06409013","Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma","Sarcoma Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography","Inclusion Criteria:\n\n* Patients with biopsy-proven bone or soft tissue sarcoma undergoing resection\n\nExclusion Criteria:\n\n* \\* Age less than 18\n\n  * Chronic kidney disease\n  * Anaphylaxis to dyes",{"count":314,"type":21},50,"This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.",[28,92],"2026-02-04",{"date":319,"type":38},"2026-02-06",{"date":321,"type":38},"2024-03-14",{"date":323,"type":21},"2027-03-30",{"name":234,"class":45},{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":16,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":79},"100271320","phase-1-in-vivo-lung-perfusion-for-pulmonary-metastases-of-sarcoma-100271320","NCT02811523","In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma","In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas","Inclusion Criteria:\n\n* Diagnosis of Soft Tissue or Osteogenic Sarcoma\n* Presence of bilateral pulmonary metastases\n* 3 or more lung lesions in total\n* Age less than 65 years\n* ECOG 0-2\n* Absence of extra-pulmonary disease\n* Contralateral disease amenable to surgery or radiation\n* All lung lesions in the lung to be treated with IVLP can be resected with wedge or segmental resections (non-IVLP treated lung will be treated with radiation or surgery 4-12 weeks prior to IVLP)\n\nExclusion Criteria:\n\n* Patient has previously received more than 450 mg of doxorubicin\n* Left Ventricular Ejection Fraction \\\u003C50%\n* History of significant pulmonary disease or pneumonitis\n* Pregnant or lactating females\n* Age 65 years or older, or less than 18 years\n* Inability to understand the informed consent process\n* Hypersenstivity to doxorubicin\n* Current participation in another therapeutic clinical trial\n* Previous lung metastatectomy","0 Years","64 Years",{"count":335,"type":21},17,[144],"Sarcoma which has spread to the lungs is most often treated with surgery. Even with surgery, most patients will not be cured and will die from their disease, probably because of small cancer cells that are present in the lungs at the time of surgery, but cannot be seen or detected. It is for this reason that we are looking for a better treatment. Giving chemotherapy after surgery is generally not recommended because it has significant side effects and no benefit has been proven.\n\nThis study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). This is a Phase I, non-randomized, dose escalation study that will act as a pilot study for a larger prospective, multicenter, controlled clinical trial. Patients who have bilateral disease will have one lung undergo IVLP and the other lung will remain untreated with the IVLP (the other lung will be treated as current standard of care - either surgery or radiation) as a control lung. The patients will undergo a posterolateral thoracotomy. Lung metastases will be identified by visualization or palpation. After surgical isolation of the lung by proximal control of pulmonary artery and veins, IVLP will be initiated. After 3 hours of IVLP, the lung metastases will be removed in the usual fashion. Patients will be cared for post-surgery according to institutional standards. The patients will be followed for up to 2 years. The primary endpoint is safety. Secondary endpoints include additional safety endpoints and efficacy.",[28,92,339],"Pulmonary Metastases","2025-11-25",{"date":342,"type":38},"2025-11-26",{"date":344,"type":38},"2016-02",{"date":346,"type":21},"2030-09",{"name":348,"class":45},"University Health Network, Toronto",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":357,"enrollmentInfo":358,"targetDuration":360,"studyType":166,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":374},"100376472","observational-study-for-quality-assessment-of-sarcoma-in-european-and-latin-american-multidisciplinary-network-100376472","NCT04181970","Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK","Observational Study, for Quality Assessment, of Sarcoma As a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK","(SELNET)","Inclusion Criteria:\n\n* Histological diagnosis of soft-tissue sarcoma, GIST or bone sarcoma (all subtypes) from January 2005 until Juny\u002FSeptember 2023.\n* ≥ 18 years\n* Available clinical and treatment information\n\nExclusion Criteria:\n\nThere is no exclusion criteria","120 Years",{"count":359,"type":21},5000,"30 Months","Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as relapse free survival, overall survival, percentage of amputation, etc.\n\nExpert pathology peer review will be performed to detect differences between expert and non-expert centers as well as differences in treatment and patient prognosis.\n\nTumor samples of 4 types of sarcoma would also be included in translational research to detect biomarkers and produce preclinical models.",[363,364,28],"Soft-tissue Sarcoma","Gastrointestinal Stromal Tumors","2025-03-18",{"date":367,"type":38},"2025-03-21",{"date":369,"type":38},"2019-06-30",{"date":371,"type":21},"2026-09-30",{"name":373,"class":45},"Grupo Espanol de Investigacion en Sarcomas",9,{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":54,"enrollmentInfo":383,"targetDuration":4,"studyType":22,"phases":384,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":79},"100567501","phase-3-chemo-immunotherapy-in-patients-under-18-years-of-age-with-bone-and-soft-tissue-sarcomas-100567501","NCT06669013","Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy","FollowTheDIN","Inclusion Criteria:\n\n1. Signed written informed consent form;\n2. Age under 18 years of age;\n3. Histologically confirmed GD2-positive osteogenic sarcoma, Ewing's sarcoma, soft tissue and undifferentiated sarcomas;\n4. Prior to study enrollment, patients must have been treated with one or more lines of adequate chemotherapy and must have relapsed on this therapy or have refractoriness to it;\n5. General satisfactory condition of the patient (Lansky scale activity 80-100% (children under 16 years of age), Karnofsky scale 80-100% (children over 16 years of age); ECOG - 0-1);\n6. Sufficient cardiopulmonary reserves of the patient's organism (ECG (ELECTROCARDIOGRAPHY) data within normal limits, ventricular ejection fraction \\> 75% of the upper limit of normal;\n7. Adequate liver function (ALT (ALANINE AMINOTRANSFERASE) ≤ 2.5 \\* VGN, AST (ASPARTATE AMINOTRANSFERASE) ≤ 2.5 \\* VGN), kidney (creatinine \\\u003C1.5 \\* VGN), red bone marrow (granulocytes\\> 2.0 \\* 109\u002FL, platelets\\> 150 \\* 109\u002FL).\n\n   Six months later, two additional criteria were formulated:\n8. Life expectancy at the time of initiation of therapy within the framework of the study is not less than 12 months\n9. Oligometastasis disease (presence of 1 to 5 distant metastatic foci) at restaging at the time of the decision to include the patient in the study;\n\nExclusion Criteria:\n\n1. Withdrawal of consent by the patient or his\u002Fher parent\u002Fguardian.\n2. Exclusion of the patient by the investigator for safety or ethical reasons.",{"count":20,"type":21},[385],"PHASE3","Data from 40 patients are planned to be included in the study to randomize approximately 10 patients.\n\nThis study involves patients with advanced\u002Fmetastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced\u002Fmetastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced\u002Fmetastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.\n\nAll patients will receive therapy until disease progression (a total of 6 courses of immunotherapy).\n\nThe primary objective of the study is to determine the efficacy and safety of dinutuximab beta with investigator's choice of chemotherapy.",[28,388,389],"Embryonal Rhabdomyosarcoma","Alveolar Rhabdomyosarcoma","2024-10-31",{"date":392,"type":38},"2024-11-01",{"date":394,"type":38},"2021-05-20",{"date":396,"type":21},"2025-09",{"name":398,"class":45},"N.N. Petrov National Medical Research Center of Oncology",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":407,"targetDuration":409,"studyType":166,"phases":4,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":4},"100478829","registry-for-children-adolescents-and-adults-with-osteosarcoma-and-biologically-related-bone-sarcomas-100478829","NCT05515068","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas","Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry)","COSS-Registry","Inclusion Criteria:\n\n* high-grade osteosarcoma (conventional and non-conventional)\n* parosteal, periosteal or extraosseous osteosarcoma\n* low grade central osteosarcoma\n* (osseous) Undifferentiated pleomorphic sarcoma (UPS)\n* (osseous) leiomyosarcoma\n* (osseous) dedifferentiated chondrosarcoma\n* (osseous) mesenchymal chondrosarcoma\n* (osseous) fibrosarcoma\n* (osseous) angiosarcoma\n* informed consent\n\nExclusion Criteria:\n\n* no informed consent",{"count":408,"type":21},1000,"20 Years","The Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas (COSS-Registry) is a non-interventional, multicentric, international, clinical and epidemiologic patient registry. The COSS-Registry collects key data on osteosarcomas or biologically related bone sarcomas. With that data collection we want to gain new scientific insights and results about this tumor disease, prognosis, surveillance and long-term effects.\n\nBesides the data collection we would also like to foster the collection of biomaterial (tumor specimen and blood samples) for scientific research.\n\nThe stored material will be used to perform cell and molecular biological analyses to identify the causes of osteosarcoma, the prognosis and possible new treatment options.\n\nAs a starting point the donated biomaterial of registered patients will be analyzed firstly for the presence of a tumor predisposition by germline mutations.\n\nIn case of detected genetic variations that are related to the tumor disease and which may affect the patient's health and follow-up care (because of the potentially increased risk of developing other malignant tumors), affected patients will be informed and referred to genetic counseling.\n\nRegistry patients will be asked at the time of diagnosis if they wish to be informed about germline variants detected as part of the study procedures.",[169,412,28,413,414,415,416,417,418,419,172,420,421,422,284,423,424,425,426,427,428,429,430,431,432,433],"Bone Tumor","High Grade Sarcoma","Osteoblastic Osteosarcoma","Chondroblastic Osteosarcoma","Fibroblastic Osteosarcoma","Conventional Osteosarcoma","Conventional Central Osteosarcoma of Bone","Low Grade Central Osteosarcoma","Osseous Tumor","Small Cell Osteosarcoma","Telangiectatic Osteosarcoma","Parosteal Osteosarcoma","Periosteal Osteosarcoma","Extraskeletal Osteosarcoma","Recurrent Osteosarcoma","High Grade Surface Osteosarcoma","Osseous Angiosarcoma","Osseous Fibrosarcoma","Osseous Leiomyosarcoma","Osseous Dedifferentiated Chondrosarcoma","Osseous Mesenchymal Chondrosarcoma","Clear Cell Osteosarcoma","2022-08-24",{"date":436,"type":38},"2022-08-25",{"date":438,"type":21},"2022-09",{"date":440,"type":21},"2032-03",{"name":442,"class":45},"Klinikum Stuttgart"]